Tolerability of β-blockers metabolized via cytochrome P450 2D6 is sex-dependent

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 5, 2006, Pages 551-553

  Thürmann, Petra A ^a   Haack, Sara ^a   Werner, Ulrike ^a   Szymanski, Jacek ^a   Haase, Grit ^b   Drewelow, Bernd ^b   Reimann, Ilselore R ^c   Hippius, Marion ^d   Siegmund, Werner ^e   May, Karen ^e   Hasford, Joerg ^f  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Germany   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CYTOCHROME P450 2D6; DIGITOXIN; METOPROLOL; NEBIVOLOL; PROPRANOLOL; SOTALOL; VERAPAMIL;

BLOOD LEVEL; BRADYCARDIA; DRUG ACTIVITY; DRUG DISPOSITION; DRUG TOLERABILITY; FISHER EXACT TEST; HUMAN; HYPERTENSION; HYPOTENSION; LETTER; PHENOTYPE; PRIORITY JOURNAL; RANK SUM TEST; SEX DIFFERENCE; SYNCOPE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BRADYCARDIA; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; HYPOTENSION; LONGITUDINAL STUDIES; MALE; METOPROLOL; MIDDLE AGED; SEX FACTORS; SYNCOPE;

EID: 33750936038     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.08.004     Document Type: Letter

References (7)

1. Wuttke H., Rau T., Heide R., Bergmann K., Bohm M., Weil J., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72 (2002) 429-437
2. Flockhart D. Cytochrome P450 drug-interaction table. Indiana University School of Medicine Web site. Last updated June 22, 2006. Available from: URL:http://www.medicine.iupui.edu/flockhart/table.htm. Accessed July 13, 2006.
3. Micromedex healthcare series 2006. Available at: URL:www.micromedex.com. Accessed July 13, 2006.
4. Fux R., Morike K., Prohmer A.M., Delabar U., Schwab M., Schaeffeler E., et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78 (2005) 378-387
5. Jochmann N., Stangl K., Garbe E., Baumann G., and Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26 (2005) 1585-1595
6. Schneeweiss S., Hasford J., Goettler M., Hoffmann A., Riethling A.K., and Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 58 (2002) 285-291
7. Pittrow D., Kirch W., Bramlage P., Lehnert H., Höfler M., Unger T., et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 60 (2004) 135-142